NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Vaxcyte, Inc. (PCVX) Stock Analysis

Vaxcyte, Inc. (PCVX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PCVX

$63.23

−$3.00 (−4.53%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PCVX with… →

PCVX Key Statistics

As of Oct 21, 2026
Trading
Open
$66.02
Previous Close
$66.23
Day's Range
63.11–67.47
52-Week Range
39.87–90.75
Volume
3.27M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.23
Valuation
Market Cap
$9.95B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.62
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$766.63M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
157.39M
1-Year Return
+49.30%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
1.92M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PCVX closed at $63.23, +49.30% over 1 year.

Vaxcyte, Inc. (PCVX) has a market capitalization of $9.95B.

In fiscal 2025, PCVX reported revenue of $0.00.

PCVX Stock Return by Calendar Year

Vaxcyte, Inc. (PCVX) return since Jun 2020: what $10,000 became

1 year
$10,000 $14,930
+49.30%
5 years
$10,000 $28,077
+180.77%
Since Jun 2020
$10,000 $24,180
+141.80%

If you had invested $10,000 in Vaxcyte, Inc. (PCVX) at the close on June 12, 2020, the earliest close on record here, it would have been worth $24,180 at the close on October 21, 2026: +141.80% in total, +14.90% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+37.04%
2025−43.64%
2024+30.35%
2023+30.97%
2022+101.56%
2021−10.46%
2020 (partial year)+1.61%

As of October 21, 2026.

PCVX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$766.63M—
2024$0.00−$463.93M—
2023$0.00−$402.27M—
2022$0.00−$223.49M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$923.68M−$766.63M—
2024$0.00—−$569.55M−$463.93M—
2023$0.00—−$393.04M−$402.27M—
2022$0.00—−$209.26M−$223.49M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Vaxcyte, Inc. (PCVX) at $9.95B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 507.

The 52-week range on file runs from $39.87 to $90.75. PCVX last closed at $63.23 on October 21, 2026. That is −$3.00 (−4.53%) against the previous close. The latest close sits 58.59% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $766.63M. Earnings per share on a trailing basis come to −7.62.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the total return is +49.30%. Across 5 years the annualized return works out at +22.93%. The reported beta is 1.23. Annualized volatility over the trailing 6 years is 65.05%.

Growth & Income

No dividend is on file for PCVX.

So far in 2026 the total return is +37.04%. Across the complete calendar years on file, 2022 returned +101.56% and 2025 returned −43.64%. Of the 5 complete calendar years on file, 3 finished higher.

Peer Comparison

Vaxcyte, Inc. (PCVX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Vaxcyte, Inc. PCVX $9.95B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Vaxcyte, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Visit website →